CD19-specific CAR T Cells for R/R ALL
Condition: B-cell Acute Lymphoblastic Leukemia Intervention: Biological: CD19-CAR-T Cells Sponsors: Sabz Biomedicals; Ministry of Health and Medical Education; Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2020 Category: Research Source Type: clinical trials
The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A structured summary of a study protocol for a randomised controlled trial
This study aims to assess the effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19).Trial designThis is a Double-Blind, Placebo-Controlled, Parallel Arm, Randomized Phase ΙΙ Clinical Trial.ParticipantsPatients with the confirmed COVID-19 based on the PCR test are eligible to participate in the trial if they are 18 to 75 years of age and have no history of the current use of warfarin or propolis supplement and presence of sensitivity to bee products. Patients will be recruited from the Al-Zahra hospital in Isfahan city, Isfahan, Iran.Intervention and comparatorParticipants (N=40) ...
Source: Trials - December 3, 2020 Category: Research Source Type: clinical trials
Evaluating the efficacy and safety of the myrtle ( Myrtus communis ) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
This study aims at investigating the effect ofM. communis fruit for treatment of COVID-19 disease.MethodsWe are performing an open-label randomized controlled trial on outpatients clinically suspected to COVID-19 disease in the age range of 18 –65 years old with mild to moderate symptoms and without respiratory distress. Patients in both groups (M. communis and control) receive conventional therapy, but those inM. communis group getM. communis preparation in addition to conventional therapy. Intervention will continue for 5 days and the study outcomes including clinical status as well as mortality rate and adverse e...
Source: Trials - November 26, 2020 Category: Research Source Type: clinical trials
The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation: A structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesAssessing the effect of surfactant on clinical outcome in patients with COVID-19 under mechanical ventilationTrial designSingle centre, two arm, parallel group (1:1 allocation ratio), randomised superiority trial with blinded care and outcome assessment.ParticipantsInclusion criteria: Adult COVID-19 patients admitted to the ICU in Modarres hospital, Tehran, Iran (age range of 18 to 99 years) with moderate to severe ARDS (based on definition of P/F ratio) requiring auxiliary respiratory devices (either intubation or face mask).Exclusion criteria:● Existence of a major underlying pulmonary disease in addi...
Source: Trials - November 11, 2020 Category: Research Source Type: clinical trials
Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial
This study is being conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.Intervention and comparatorPatients are randomly assigned to four groups. The first group (A) will take one capsule containing 5 mg of boron compounds twice a day for two weeks. The second group (B) will take one capsule containing 200 mg oleoylethanolamide twice a day for two weeks. The third group (C) will take one capsule containing 5 mg boron compounds with 200 mg oleoylethanolamide twice a day for two weeks, and the fourth group (D) does not receive any additional treatment other than routine treatments. Boron-cont...
Source: Trials - October 27, 2020 Category: Research Source Type: clinical trials
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesWe will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill.Trial designThis is a phase 3, single-center, randomized, open-label, controlled trial with a parallel-group design carried out at Shahid Mohammadi Hospital, Bandar Abbas, Iran.ParticipantsAll patients with age ≥ 20 years admitted at the Severe Acute Respiratory Syndrome Departments of the Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria.Inclusion criteria:Confirme...
Source: Trials - October 27, 2020 Category: Research Source Type: clinical trials
